Efficacy of Apixaban in Malignancy With Deep Venous Thrombosis
Status:
Recruiting
Trial end date:
2020-07-03
Target enrollment:
Participant gender:
Summary
The aim of study was to evaluate the efficacy and safety of Apixaban in patients with acute
deep venous thrombosis and active malignancy compared with weight adjusted subcutaneous
(LMWH). It was hypothesised that Apixaban could be as effective as rivaroxiban and edoxaban
in treatment of patients with acute DVT and active malignancy with a lower risk of bleeding
especially in those with GIT cancer.